by | Aug 30, 2024 | Lupus Foundation of America, News & Events
In a new phase 3, double-blind study, researchers explored the efficacy and safety of combination therapy using subcutaneous (SC) belimumab and rituximab for the treatment of active systemic lupus erythematosus (SLE). This study sought to evaluate if sequential...
by | Aug 29, 2024 | Lupus Foundation of America, News & Events
The Harnessing Endogenous Regulators Against CLE Study (HERACLES) is planned to begin in early 2025 and will serve as a proof-of-concept study for the investigational therapy, SOF-SKN™, for treatment of cutaneous lupus erythematosus disease (CLE), or lupus skin...
by | Aug 26, 2024 | Lupus Foundation of America, News & Events
A new study published in Lupus Science & Medicine found an advanced neuroimaging method called a structural MRI can identify total and regional brain abnormalities associated with cognitive dysfunction (CD) in people with systemic lupus erythematosus (SLE). CD is...
by | Aug 23, 2024 | Lupus Foundation of America, News & Events
In a new study, researchers examined the efficacy and impact of CD19 CAR T cell therapy on B cells, specifically exploring its ability to deplete B cells in deep tissues and understand the therapeutic potential for people with autoimmune diseases, like lupus. CAR T...
by | Aug 22, 2024 | Lupus Foundation of America, News & Events
In a new study, researchers examined the associations between health literacy with patient-reported outcomes and systemic lupus erythematosus (SLE) disease activity and damage. Findings showed that limited health literacy remains a critical social determinant of...
by | Aug 20, 2024 | Lupus Foundation of America, News & Events
The new drug application for the investigational therapy, Equecabtagene Autoleucel or Eque-cel, for treatment of lupus nephritis (LN) and non-renalsystemic lupus erythematosus (SLE) was approved by the U.S. Food and Drug Administration. Eque-cell is a fully human...
